Michael Ihnat to Doxorubicin
This is a "connection" page, showing publications Michael Ihnat has written about Doxorubicin.
Connection Strength
0.254
-
Development and characterization of a preclinical model of breast cancer lung micrometastatic to macrometastatic progression. PLoS One. 2014; 9(5):e98624.
Score: 0.112
-
A novel multidrug resistance phenotype of bladder tumor cells grown on Matrigel or SIS gel. Cancer Lett. 2005 Jan 20; 217(2):171-80.
Score: 0.059
-
Effects of mitomycin C and carboplatin pretreatment on multidrug resistance-associated P-glycoprotein expression and on subsequent suppression of tumor growth by doxorubicin and paclitaxel in human metastatic breast cancer xenografted nude mice. Oncol Res. 1999; 11(7):303-10.
Score: 0.039
-
Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents. Clin Cancer Res. 1997 Aug; 3(8):1339-46.
Score: 0.035
-
Growth of human tumor cells in macroporous microcarriers results in p53-independent, decreased cisplatin sensitivity relative to monolayers. Mol Pharmacol. 1999 May; 55(5):938-47.
Score: 0.010